文献速递淋巴瘤

整合[18F]FDG-PET影像组学与液体活检改善新诊断弥漫性大B细胞淋巴瘤结局预测

Integration of [18F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma.
PubMed 文献 · Leukemia · 2025-07-08

在120例接受R-CHOP治疗的新诊断弥漫性大B细胞淋巴瘤真实队列中,以SUV阈值4.0采集PET/CT影像组学变量,并用CAPP-seq进行ctDNA分析。tMTV、tTLG和Dmax在校正ctDNA水平后保留独立预后价值并组成高风险PET变量。ctDNA-high与高风险PET独立预测PFS并组成2因素模型(PFS的C指数0.712,OS的0.696);BN2/EZB/ST2分子聚类进一步纳入3因素评分(PFS的C指数0.745,OS的0.746),识别出极高危组(n=22,40个月PFS 12.1%)。

要点

  • tMTV、tTLG和Dmax在校正ctDNA水平后保留独立预后价值,组成高风险PET变量。
  • ctDNA-high与高风险PET独立预测PFS,组成2因素模型,PFS的C指数0.712、OS的C指数0.696。
  • BN2/EZB/ST2聚类纳入3因素评分后,PFS的C指数0.745、OS的C指数0.746。

核心结论

  • 整合[18F]FDG-PET影像组学与液体活检可改善新诊断弥漫性大B细胞淋巴瘤的结局预测。
  • 3因素预后评分识别出极高危组(n=22,40个月PFS 12.1%),该组应优先进行早期疗效评估并获取新型药物。

研究设计与样本

  • 真实世界队列研究,纳入新诊断弥漫性大B细胞淋巴瘤患者120例,均接受R-CHOP治疗。
  • 以标准化摄取值(SUV)阈值4.0采集PET/CT影像组学变量(SUVmax、tMTV、tTLG和Dmax),并通过CAPP-seq进行循环肿瘤DNA(ctDNA)分析获取基线ctDNA水平和LymphGen分子聚类。
  • PET/CT参数与ctDNA水平的最佳截断值均通过max-stat统计法确定。

主要发现

  • tMTV、tTLG和Dmax在校正ctDNA水平后保留独立预后价值,并组成名为高风险PET的变量。
  • 多因素分析显示ctDNA-high与高风险PET独立预测PFS,并组成2因素预后模型(PFS的C指数0.712,OS的C指数0.696)。
  • BN2/EZB/ST2聚类在针对2因素模型变量校正后维持与更好PFS的独立关联,因此被纳入3因素预后评分(PFS的C指数0.745,OS的C指数0.746)。
  • 3因素预后评分识别出极高危组(n=22,40个月PFS 12.1%)。

关键数值与推荐

  • PET/CT影像组学变量采集采用SUV阈值4.0。
  • 2因素预后模型:PFS的C指数0.712,OS的C指数0.696。
  • 3因素预后评分:PFS的C指数0.745,OS的C指数0.746。
  • 极高危组:n=22,40个月PFS 12.1%。

临床怎么用

  • 作者认为,3因素预后评分识别出的极高危组患者应优先进行早期疗效评估并获取新型药物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Early identification of relapsing/refractory diffuse large B-cell lymphoma (DLBCL) represents an unmet clinical need. A real-life cohort of newly diagnosed DLBCL (n = 120) treated with R-CHOP was investigated. Using the standardized uptake value (SUV) threshold of 4.0, PET/CT radiomics variables (SUVmax, tMTV, tTLG and Dmax) were collected. Circulating tumor DNA (ctDNA) analysis by CAPP-seq yielded baseline ctDNA levels and LymphGen molecular clustering. The best cut-off for both PET/CT parameters and ctDNA levels were identified by max-stat statistics. tMTV, tTLG and Dmax retained independent prognostic value when adjusted for ctDNA levels and were grouped together in a variable named high-risk PET. By multivariate analysis, ctDNA-high and high-risk PET independently predicted PFS and were combined into a 2-factor prognostic model (C-indices: 0.712 for PFS and 0.696 for OS). Molecular clustering, by capturing high-risk biological features of DLBCL, further improved outcome prediction. Consistently, BN2/EZB/ST2 clusters maintained an independent association with better PFS when adjusted for the 2-factor model variables and were therefore included in a 3-factor prognostic score (C-indices: 0.745 for PFS and 0.746 for OS), that identified a very high-risk group of patients (n = 22, 40-month PFS 12.1%) which should be prioritized for early response evaluation and for access to novel agents.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Dondolin R, Garrou F, Almasri M, et al. Integration of [18F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma. Leukemia. 2025. PMID: 40629066. doi:10.1038/s41375-025-02688-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。